Compare Anheuser-Busch Inbev SA (BUD) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Teladoc Health Inc — how do they compare? Anheuser-Busch Inbev SA trades at $78.88 (market cap $153.45B), while Teladoc Health Inc trades at $9.34 (market cap $1.67B). The key difference: Anheuser-Busch Inbev SA is far larger — about 91.9× Teladoc Health Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| BUD | TDOC | |
|---|---|---|
Market Cap | $153.45B | $1.67B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $9.65 |
52-Week Low | $57.10 | $4.47 |
Enterprise Value | $214.64B | $1.96B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
TDOC trades at $9.65, up 3.99% with bullish technical signals but mixed fundamentals. Revenue remains stable around $2.5B, yet net losses persist with a -6.81% margin. Analyst consensus is cautious with 64% hold ratings, though recent partnerships like Walmart's Better Care show growth potential. Cash flow trends indicate significant net outflows, raising liquidity concerns despite a solid gross margin of 69.29%.
Outlook hinges on cost management and partnership execution; risks include sustained losses and high debt. The stock offers speculative upside if profitability improves, but investor patience is required amid competitive pressures and volatile sentiment. Current price near resistance at $10 suggests limited near-term upside without positive earnings surprises.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
